Latest news with #AaronDumas
Associated Press
15 hours ago
- Business
- Associated Press
KNBE Stock News: Former KnowBe4 (KNBE) Stockholders Should Contact Robbins LLP for Information Regarding the Securities Fraud Class Action on Their Behalf
SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors (i) who held KnowBe4, Inc. (NASDAQ: KNBE) common stock as of the December 7, 2022, record date that were entitled to vote on the 'take private' acquisition ('Merger') by Vista Equity Partners Management LLC and its affiliates, or (ii) sold shares of KnowBe4 common stock from the October 12, 2022, announcement date through the February 1, 2023, close of the Merger. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that KnowBe4, Inc. (KNBE) Misled Investors Regarding its Acquisition by Vista Equity Partners Management LLC According to the complaint, defendants issued or caused to be issued SEC filings that contained numerous false or misleading statements or omitted material facts concerning: (i) the unfair sales process that provided distinct advantages to Vista; (ii) the Special Committee's purported independence; (iii) KKR's intention to increase its rollover or reinvestment into the post-close KnowBe4 by 50-100% after learning the deal price; (iv) the Special Committee's favoritism towards Vista over other potential bidders; (v) the Special Committee's failure to consider strategic alternatives other than a sale of KnowBe4; and (vi) the Company's largest non-Rollover Stockholder, Mitnick, owed his personal fortune and professional legitimacy to Sjouwerman, and therefore was not independent from members of the Control Group. These filings contained materially false and misleading statements and omissions, thereby denying stockholders an appropriately informed vote on the Merger and an appropriately informed opportunity to decide whether to accept the Merger consideration or instead exercise their appraisal rights. What Now: You may be eligible to participate in the class action against KnowBe4, Inc. Shareholders who want to serve as lead plaintiff for the class must file a motion for lead plaintiff by August 5, 2025. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against KnowBe4, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome.
Associated Press
07-06-2025
- Business
- Associated Press
FTRE Investor Notice: Stockholder Rights Law Firm Robbins LLP Reminds Shareholders of the Class Action Against Fortrea Holdings, Inc.
SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Fortrea Holdings, Inc. (NASDAQ: FTRE) securities between July 3, 2023 and February 28, 2025. Fortrea is a global contract research organization ('CRO') that provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that Fortrea Holdings, Inc. (FTRE) Misled Investors Regarding the Progress of its Pre-Spin Projects The complaint alleges that Fortrea was formerly the clinical development and commercialization services business of Labcorp Holdings Inc., a life sciences and healthcare company. In June 2023, Labcorp spun off Fortrea as a standalone, publicly traded company. In connection with the Spin-Off, Labcorp and Fortrea entered into several transition services agreements (the 'TSAs'), pursuant to which Fortrea pays Labcorp to provide certain transitional services for a set period, including information technology applications, network and security support and hosting, as well as finance, human resources, marketing, and other administrative support. On March 3, 2025, Fortrea announced its fourth quarter and full year 2024 financial results, disclosing that its 'targeted revenue and adjusted EBITDA trajectories for 2025 [were] not in line with [its] prior expectations.' Specifically, in an earnings call held that same day, Fortrea revealed that the Company's Pre-Spin projects are 'late in their life cycle [and] have less revenue and less profitability than expected for 2025' and that 'post-spin work is not coming on fast enough to offset the pre-spin contract economics.' The Company also said this 'older versus newer mix issue will continue to negatively impact [Fortrea's] financial performance during 2025.' On this news, Fortrea's stock price fell $3.47 per share, or 25.05%, to close at $10.38 per share on March 3, 2025. According to the complaint, during the class period, defendants failed to disclose that: (i) Fortrea overestimated the amount of revenue the Pre-Spin Projects were likely to contribute to the Company's 2025 earnings; (ii) Fortrea overstated the cost savings it would likely achieve by exiting the TSAs; (iii) as a result, the Company's previously announced EBITDA targets for 2025 were inflated; and (iv) accordingly, the viability of the Company's post-Spin-Off business model, as well as its business and/or financial prospects, were overstated. What Now: You may be eligible to participate in the class action against Fortrea Holdings, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motion with the court by August 1, 2025. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Fortrea Holdings, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome. A photo accompanying this announcement is available at
Malaysian Reserve
30-05-2025
- Business
- Malaysian Reserve
OGN Stockholders with Large Losses Should Contact Robbins LLP for Information About the Class Action Lawsuit Against Organon & Co.
SAN DIEGO, May 30, 2025 /PRNewswire/ — Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Organon & Co. (NYSE: OGN) securities between October 31, 2024 and April 30, 2025. Organon is a global healthcare company with a primary focus on improving the health of women throughout their lives. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that Organon & Co. (ORG) Misled Investors Regarding its Debt Reduction Strategy According to the complaint, during the class period, defendants provided investors with material information concerning Organon's prioritization of its capital allocation strategy through regular, quarterly dividends. Defendants' statements included, among other things, reassurance that capital allocation through the dividends was a '#1 capital allocation priority' and that Organon was committed to consistent deployment of capital. The complaint alleges that while defendants were making these positive statements, they were concealing the high priority of Organon's debt reduction strategy following the Company's acquisition of Dermavant, resulting in a 70% decrease for the regular quarterly dividend. The complaint further alleges that the truth came out on May 1, 2025, when Organon announced its first quarter 2025 results wherein management had reset the Company's dividend payout, from $0.28 to $0.02 to recapture capital for the Company. On this news, the price of Organon's common stock declined from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, a decline of more than 27%. What Now: You may be eligible to participate in the class action against Organon & Co. Shareholders who want to serve as lead plaintiff for the class you should contact the firm. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Organon & Co. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome.
Malaysian Reserve
30-05-2025
- Business
- Malaysian Reserve
Robbins LLP Reminds Investors With Large Losses to Contact the Law Firm for Information About the Class Action Lawsuit Against DoubleVerify Holdings, Inc.
SAN DIEGO, May 30, 2025 /PRNewswire/ — Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired DoubleVerify Holdings, Inc. (NYSE: DV) common stock between November 10, 2023 and February 27, 2025. DoubleVerify operates a software platform for digital media measurement and advertising optimization services. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that DoubleVerify Holdings, Inc. (DV) Misled Investors Regarding its Business Prospects According to the complaint, during the class period, defendants failed to disclose that: (a) DoubleVerify's customers were shifting their ad spending from open exchanges to closed platforms, where the Company's technological capabilities were limited and competed directly with native tools provided by platforms like Meta Platforms and Amazon; (b) DoubleVerify's ability to monetize on its Activation Services was limited because the development of its technology for closed platforms was significantly more expensive and time-consuming than disclosed to investors; (c) DoubleVerify's Activation Services in connection with certain closed platforms would take several years to monetize; (d) DoubleVerify's competitors were better positioned to incorporate AI into their offerings on closed platforms, which impaired DoubleVerify's ability to compete effectively and adversely impacted the Company's profits; (e) DoubleVerify systematically overbilled its customers for ad impressions served to declared bots operating out of known data center server farms; and (f) DoubleVerify's risk disclosures were materially false and misleading because they characterized adverse facts that had already materialized as mere possibilities. The complaint alleges that the truth was revealed on February 27, 2025, when DoubleVerify reported lower-than-expected fourth quarter 2024 sales and earnings due in part to reduced customer spending and the suspension of DoubleVerify services by a large customer. Defendants also disclosed that the shift of ad dollars from open exchanges to closed platforms was negatively impacting the Company. On this news, DoubleVerify's stock price dropped $7.83 per share, or 36%, from a closing price of $21.73 on February 27, 2025, to a closing price of $13.90 on February 28, 2025. What Now: You may be eligible to participate in the class action against DoubleVerify Holdings, Inc. Shareholders who want to serve as lead plaintiff for the class are required to file their papers with the court by July 15, 2025. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against DoubleVerify Holdings, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome.
Malaysian Reserve
28-05-2025
- Business
- Malaysian Reserve
ZBIO STOCKHOLDERS: Contact Robbins LLP for Information About How to Lead the Class Action Against Zenas BioPharma, Inc.
SAN DIEGO, May 27, 2025 /PRNewswire/ — Robbins LLP reminds stockholders that a class action was filed on behalf of all persons who purchased or otherwise acquired Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with Zenas BioPharma's September 2024 initial public offering. Zenas BioPharma purports to be a 'clinical stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies for patients in need.' For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that Zenas BioPharma, Inc. (ZBIO) Misled Investors in Connection with its IPO According to the complaint, defendants failed to disclose that in connection with its IPO, Zenas BioPharma materially overstated the amount of time that it would be able to fund its operations using existing cash and expected net proceeds from the IPO. On November 12, 2024, the Company filed with the SEC its quarterly report on Form 10-Q for the period ended September 30, 2024, stating that the Company could fund its operations for the following twelve months, not twenty-four, as it had stated in the Registration Statement. Since the IPO, and as a result of the disclosure of material adverse facts omitted from Zenas BioPharma's Registration Statement, Zenas BioPharma's share price has fallen substantially below its IPO price. As of the close of trading on April 15, 2025, the closing price of Zenas BioPharma stock was $8.72, 48.7% below the IPO price. What Now: You may be eligible to participate in the class action against Zenas BioPharma, Inc. Shareholders who want to serve as lead plaintiff for the class must file their papers with the court by June 16, 2025. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Zenas BioPharma, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome. Facebook:
